Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
